|
Intangible Assets (Narrative) (Details) (USD $)
|
12 Months Ended | 3 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2011
years
|
Dec. 31, 2010
|
Dec. 31, 2009
|
Dec. 31, 2010
IPR&D [Member]
|
Dec. 31, 2011
Arresto Biosciences, Inc. [Member]
IPR&D [Member]
|
Dec. 31, 2011
Calistoga Pharmaceuticals, Inc. [Member]
IPR&D [Member]
|
Dec. 31, 2011
CV Therapeutics [Member]
|
Dec. 31, 2010
CV Therapeutics [Member]
IPR&D [Member]
|
Dec. 31, 2011
CGI Pharmaceuticals [Member]
IPR&D [Member]
|
Dec. 31, 2010
CGI Pharmaceuticals [Member]
IPR&D [Member]
|
|
| Acquired Finite-Lived Intangible Assets [Line Items] | ||||||||||
| Amortization expense | $ 69,600,000 | $ 59,900,000 | $ 43,400,000 | |||||||
| Weighted-average amortization period of intangible assets, in years | 10 | |||||||||
| Indefinite-lived intangible assets | 266,200,000 | 29,530,000 | 29,500,000 | 117,000,000 | 149,200,000 | 2,900,000 | 26,600,000 | |||
| Impairment charges | 136,000,000 | 26,600,000 | ||||||||
| Finite-lived intangible assets | $ 976,195,000 | $ 973,295,000 | $ 2,900,000 | |||||||